AnnieUmbrichtMD

Internal Medicine • Baltimore, MD

Addiction Medicine

Assistant Professor, Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Umbricht is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Umbricht's full profile

Already have an account?

Office
5510 Nathan Shock Drive
Behavioral Pharmacology Research Unit
Baltimore, MD 21224
Phone+1 410-550-1917

Fax+1 410-550-1924

Education & Training

Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 1986 - 1987
University of Lausanne Faculty of MedicineClass of 1980

Certifications & Licensure

MD State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Clinical Trial of Topiramate for Cocaine Addiction Start of enrollment: 2007 Feb 01
Completed
Phase 2
Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse Start of enrollment: 2010 Jun 01
Completed
Phase 1, Phase 2
Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence
COMPLETED
PHASE2, PHASE3

Publications & Presentations

PubMed

Exposure to Bupropion-SR vs. Placebo is associated with reductions in smoking among persons receiving methadone with no stated interest in smoking cessation.
Orrin D Ware, Maxine L Stitzer, Annie Umbricht, Kelly E Dunn
Addictive Behaviors. 2025-02-01
2 citations
Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder: A Randomized Clinical Trial.
Orrin D Ware, Mary M Sweeney, Colin Cunningham, Annie Umbricht, Maxine Stitzer
JAMA Network Open. 2023-03-01
37 citations
Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.
Andrew S Huhn, Patrick H Finan, Charlene E Gamaldo, Alexis S Hammond, Annie Umbricht
Science Translational Medicine. 2022-06-22

Press Mentions

Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderNovember 4th, 2020
Double-Blind Comparison of the Two Hallucinogens Psilocybin and Dextromethorphan: Effects on CognitionJuly 30th, 2018
FDA Approves Implant to Battle Opioid AddictionMay 27th, 2016